Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
Huo Geng-wei,
Zuo Ran,
Song Ying,
Chen Wei-dong,
Chen Wen-ming,
Chong Dao-qun,
Zhang Hong-mei,
Jia Sha-sha,
Chen Peng
Affiliations
Huo Geng-wei
Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
Zuo Ran
Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
Song Ying
Department of Pharmacy, Jining No. 1 people’s Hospital, Jining 272000, Shandong, China
Chen Wei-dong
Department of Oncology, Jining No. 1 People’s Hospital, Jining 272000, Shandong, China
Chen Wen-ming
Department of Oncology, Jining No. 1 People’s Hospital, Jining 272000, Shandong, China
Chong Dao-qun
Department of Oncology, Jining No. 1 People’s Hospital, Jining 272000, Shandong, China
Zhang Hong-mei
Department of Oncology, Jining No. 1 People’s Hospital, Jining 272000, Shandong, China
Jia Sha-sha
Department of Oncology, Jining No. 1 People’s Hospital, Jining 272000, Shandong, China
Chen Peng
Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
This study evaluates the impact of the use of antibiotics on the effectiveness of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). A literature search was conducted in various electronic databases to identify studies, which evaluated the impact of antibiotic use on the survival of patients with advanced/metastatic NSCLC who have been treated with nivolumab. Six studies, comprising a total of 787 patients with 37.2% females and of age range 30–90 years, were included in the study. A lack of smoking history was reported in 14.4% of the patients. A meta-analysis was conducted in 678 and 713 patients for PFS and OS, respectively. The pooled HR was 1.95 (95% CI: 1.13–3.37, P = 0.016) for PFS and 2.70 (95% CI: 1.81–4.02, P < 0.001) for OS. Among patients exposed to antibiotics, the median PFS and OS were reduced by 1.6 months (95% CI: 1.5–1.7) and 8.8 months (95% CI: 8.5–9.1), respectively. Our study indicates that, among patients with advanced/metastatic NSCLC, the use of antibiotics with nivolumab led to a decrease in the median OS by more than 8 months. Studying the mechanism of the effect of antibiotics on the efficacy of nivolumab in patients with NSCLC should also be prioritized.